Arcus Biosciences, Inc.

Therapies ranging from small molecules to immuno-oncology drugs will make appearances at the 2025 American Society of Clinical Oncology meeting. These include drugs that are seen as having the potenti

The latest US Food and Drug Administration approval for Merck & Co.’s Welireg (belzutifan) adds to the growing number of diverse indications for the drug, which for pheochromocytoma and paragangli

The TIGIT class claimed its latest casualty as iTeos Therapeutics’ belrestotug failed to show sufficient benefit in trials of patients with non-small cell lung cancer (NSCLC) and head and neck cancer,

The biopharma sector saw another setback for the once-hot anti-TIGIT class on 3 April as BeiGene said it would end a Phase III trial of its antibody candidate ociperlimab (BGB-A1217) in non-small cell